UNITED THERAPEUTICS CORPORATION
UTHR US91307C1027
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 40% | 32% | -20% | 55% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Rothblatt Martine A CEO |
456.52 USD |
1,000 Sold |
456,520 USD |
07/10/2025 | 08/10/2025 |
| Rothblatt Martine A CEO |
445.29 USD |
1,240 Sold |
552,158 USD |
07/10/2025 | 08/10/2025 |
| Rothblatt Martine A CEO |
448.89 USD |
860 Sold |
386,045 USD |
07/10/2025 | 08/10/2025 |
| Rothblatt Martine A CEO |
454.14 USD |
900 Sold |
408,726 USD |
07/10/2025 | 08/10/2025 |
| Rothblatt Martine A CEO |
450.31 USD |
1,000 Sold |
450,310 USD |
07/10/2025 | 07/10/2025 |
| Rothblatt Martine A CEO |
451.87 USD |
2,000 Sold |
903,730 USD |
07/10/2025 | 07/10/2025 |
| Rothblatt Martine A CEO |
453.28 USD |
1,000 Sold |
453,280 USD |
07/10/2025 | 07/10/2025 |
| Benkowitz Michael COO |
454.81 USD |
100 Sold |
45,481 USD |
06/10/2025 | 06/10/2025 |
| Rothblatt Martine A CEO |
445.24 USD |
1,000 Sold |
445,240 USD |
03/10/2025 | 06/10/2025 |
| Benkowitz Michael COO |
449.82 USD |
400 Sold |
179,928 USD |
06/10/2025 | 06/10/2025 |